Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Multiple Myeloma 58Lymphoma, Large B-Cell, Diffuse 25Lymphoma, Follicular 23Lymphoma 18Leukemia, Lymphocytic, Chronic, B-Cell 17Recurrence 16Lymphoma, Non-Hodgkin 14Lymphoma, Mantle-Cell 14Lymphoma, B-Cell, Marginal Zone 12Lymphoma, B-Cell 10Neoplasms, Plasma Cell 9Waldenstrom Macroglobulinemia 6Hodgkin Disease 6Neoplasms 5Leukemia, Myeloid, Acute 5Burkitt Lymphoma 5Lymphoma, T-Cell 4Prostatic Neoplasms 3Ovarian Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Large-Cell, Anaplastic 3Leukemia 3Hematologic Neoplasms 3Sezary Syndrome 2Paraproteinemias 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Mycosis Fungoides 2Lymphoma, Large-Cell, Immunoblastic 2

Interventions

cediranib 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Thyroid cancer, Hurthle cell × Lenalidomide × Clear all
NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
127 enrolled 18 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡